North America Radiotherapy Market, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

North America Radiotherapy Market Size

• The North America radiotherapy market size was valued at USD 3.76 billion in 2024 and is expected to reach USD 8.06 billion by 2032, at a CAGR of 10.4% during the forecast period
• The market growth is growing prevalence of cancer disease, novel technology in radiotherapy for cancer treatment and increasing adoption of radiotherapy devices and procedures
• Furthermore, the market is expected to increasing healthcare expenditure for cancer treatment, growing government initiatives toward cancer treatment and rising patients’ awareness towards cancer treatment

North America Radiotherapy Market Analysis

• The North America rise in cancer prevalence, increasing adoption of advanced radiotherapy techniques such as intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT), and proton therapy, along with technological advancements in imaging and treatment planning systems, are key driving factors expected to propel the growth of the North America radiotherapy market
• Key factors such as rising demand for non-invasive and targeted cancer treatment solutions, growing investments in oncology-focused R&D, continuous innovation in radiotherapy equipment, and supportive government policies and funding for cancer care infrastructure are driving the growth of the North America radiotherapy market
• U.S dominated North America radiotherapy market with the market share of 80.41% in 2024 and is expected to grow with the fastest CAGR of 10.7% in the forecast period of 2025 to 2032 due to growing prevalence of cancer disease, novel technology in radiotherapy for cancer treatment and increasing adoption of radiotherapy devices and procedures
• The external beam radiotherapy segment dominated the market with a 60.93% in 2024 market share, growing with the CAGR of 10.7% in the forecast period of 2025 to 2032. driven growing prevalence of cancer disease, novel technology in radiotherapy for cancer treatment and increasing adoption of radiotherapy devices and procedures.

Report Scope and North America Radiotherapy Market Segmentation

North America Radiotherapy Market Trends

“Rising Demand for Advanced, Non-Invasive, and Precision-Based Cancer Treatment Solutions Across Healthcare Systems”

• Demand for advanced, non-invasive, and precision-based cancer treatment solutions is growing rapidly—driven by increasing cancer prevalence, rising patient awareness, and a shift toward personalized medicine across healthcare systems. Radiotherapy technologies address these demands by offering targeted, effective treatment options that minimize side effects and improve patient outcomes
• As healthcare providers aim to reduce treatment-related complications and enhance quality of care, there is a growing shift toward integrating advanced radiotherapy techniques such as image-guided radiotherapy (IGRT), intensity-modulated radiotherapy (IMRT), and proton therapy. This transition is crucial for meeting stringent regulatory standards, improving treatment efficacy, and supporting the North America move toward value-based care
• Major industry players such as Siemens Healthineers, Elekta, Varian (a Siemens company), and Accuray are significantly increasing their R&D efforts to develop cutting-edge radiotherapy equipment and software that offer higher precision, automation, and integration with artificial intelligence, further driving innovation and market growth
• Advancements in imaging, treatment planning, and delivery technologies—such as adaptive radiotherapy, stereotactic radiosurgery (SRS), and proton beam therapy—are enhancing treatment accuracy, patient safety, and operational efficiency. These innovations are enabling broader adoption across hospitals and specialty centers and supporting the expansion of the North America radiotherapy market

North America Radiotherapy Market Dynamics

“Growing Prevalence of Cancer Disease”

• The rising North America demand for advanced, precise, and patient-friendly cancer treatment solutions—driven by increasing cancer prevalence, growing patient awareness, and the shift toward personalized, less invasive therapies—is putting pressure on healthcare providers and manufacturers to innovate and upgrade radiotherapy technologies across hospitals, specialty clinics, and cancer centers. To meet this demand, companies are accelerating investments in next-generation radiotherapy equipment, software, and treatment planning systems to deliver higher accuracy, improved patient outcomes, and streamlined workflows at scale. These advancements are building smarter, more efficient oncology care ecosystems, much like how precision medicine is reshaping healthcare delivery
• For instance, in early 2025, researchers from leading oncology institutes highlighted the growing prominence of proton therapy and adaptive radiotherapy as transformative approaches in cancer treatment. Their studies emphasize the benefits of these cutting-edge technologies in minimizing radiation exposure to healthy tissues while enhancing tumor targeting, significantly improving patient quality of life. The report highlights the increasing importance of integrating advanced imaging and AI-driven treatment planning as vital components in the evolving landscape of cancer care, playing a critical role in enhancing radiotherapy efficacy as a personalized and integrative approach
• These investments are not only transforming radiotherapy capabilities but also enabling broader adoption of sophisticated treatment modalities across emerging markets and high-growth segments such as pediatric oncology and rare cancers. Leading players such as Siemens, Elekta, Varian (Siemens), and Accuracy are investing heavily in innovative radiotherapy systems, AI-powered software, and patient-centric solutions to maintain competitive advantage and improve treatment performance across applications
• In addition, the ongoing commitment from governments, research institutions, and private industry toward improving cancer care infrastructure and advancing radiotherapy innovation is playing a pivotal role in shaping a more effective North America oncology market. These initiatives are establishing advanced radiotherapy as a cornerstone of modern cancer treatment and a major growth driver in the transition toward safer, more precise, and patient-aligned therapies

Restraint/Challenge

“Lack of Skilled and Certified Professionals”

• The shortage of skilled and certified radiotherapy professionals remains one of the most significant restraints limiting the growth and broader adoption of advanced radiotherapy technologies worldwide. Radiotherapy treatment requires highly trained oncologists, medical physicists, dosimetrists, and radiation therapists to ensure precise treatment planning, safe delivery, and effective patient management—skills that are in short supply, especially in developing regions
• Furthermore, the complexity of modern radiotherapy techniques—such as intensity-modulated radiotherapy (IMRT), stereotactic radiosurgery (SRS), and proton therapy—demands continuous professional training and certification to keep pace with technological advancements. The lack of standardized training programs and accreditation frameworks across many countries exacerbates the issue, often leading to suboptimal treatment outcomes and limiting the ability to fully leverage sophisticated radiotherapy equipment
• For instance, in March 2025, a study by the International Atomic Energy Agency (IAEA) highlighted that many low- and middle-income countries face critical shortages of trained radiotherapy staff, which significantly delays the implementation of new treatment technologies and restricts patient access to quality care. The report emphasized the urgent need for international collaboration to develop scalable training programs and certification pathways tailored to resource-limited settings
• Similarly, a 2024 survey conducted by the American Society for Radiation Oncology (ASTRO) revealed that despite growing investments in advanced radiotherapy systems across the United States, many centers struggle to recruit and retain qualified medical physicists and dosimetrists, directly impacting treatment efficiency and patient throughput
• The shortage of skilled professionals coupled with the increasing complexity of radiotherapy techniques continues to act as a barrier to the widespread adoption and optimal utilization of radiotherapy services. While ongoing efforts in education, certification, and remote training are underway, addressing these workforce challenges remains critical to unlocking the full potential of the North America radiotherapy market

North America Radiotherapy Market Scope

The market is segmented on the basis of product, application type, procedure type, usability, end user, and distribution channel.

•        By Product and Services

On the basis of product and services, the North America radiotherapy market is segmented into services, products and software. In 2025, the services segment is expected to dominate the market with a market share of 54.36% growing with the highest CAGR of 10.7% in the forecast period of 2025 to 2032, driven by growing prevalence of cancer disease, novel technology in radiotherapy for cancer treatment and increasing adoption of radiotherapy devices and procedures.

• By Type

On the basis Type, the North America radiotherapy market is segmented into external-beam radiation therapy, internal radiation therapy, systemic radiotherapy/radiopharmaceuticals and others. In 2025, the External-Beam Radiation Therapy segment is expected to dominate the market with a market share of 63.70% growing with the highest CAGR of 10.6% in the forecast period of 2025 to 2032 driven by expected to increasing healthcare expenditure for cancer treatment, growing government initiatives toward cancer treatment and rising patients awareness towards cancer treatment.

• By Application

On the basis of Application, the North America radiotherapy market is segmented into breast cancer, lung cancer, prostate cancer, colorectal cancer, lymphoma, liver cancer, thyroid cancer, brain cancer, cervical cancer, spine cancer and others. In 2025, the breast cancer segment is expected to dominate the market with a market share of 19.37% growing with the highest CAGR of 11.6% in the forecast period of 2025 to 2032 driven by growing prevalence of cancer disease, novel technology in radiotherapy for cancer treatment and increasing adoption of radiotherapy devices and procedures.

• By End User

On the basis of End User, the North America radiotherapy market is segmented into hospitals, radiation therapy centers, specialty clinics, academic & research institutes and others. In 2024, the Hospitals segment is expected to dominate the market with a 63.00% market share and growing with the CAGR of 11.8% in the forecast period of 2025 to 2032 driven expected to increasing healthcare expenditure for cancer treatment, growing government initiatives toward cancer treatment and rising patients awareness towards cancer treatment

• By Distribution Channel

On the basis of distribution channel, the North America radiotherapy market is segmented into direct tenders, third-party distributors and others. In 2024, the direct tenders segment is expected to dominate the market with a 80.91% market share and growing with the CAGR of 10.6% in the forecast period of 2025 to 2032 driven by growing prevalence of cancer disease, novel technology in radiotherapy for cancer treatment and increasing adoption of radiotherapy devices and procedures.

North America Radiotherapy Market Regional Analysis

• U.S in North America radiotherapy market is expected to reach 6.63 million USD by 2032, from 3.02 million USD.in 2024, growing at the CAGR of 10.7% in the forecast period of 2025 to 2032
• U.S allocates a significant portion of its GDP to healthcare, ensuring substantial funding for cutting-edge cancer treatment technologies, including advanced radiotherapy procedures. In contrast, emerging markets are increasing their healthcare spending due to growing cancer prevalence and rising awareness of modern treatment options. The availability of funding from both public and private sectors plays a crucial role in expanding access to radiotherapy services North Americaly.
• In U.S, radiotherapy is widely available and integrated into standard oncology care. In contrast, emerging markets with developing healthcare infrastructure are experiencing rapid growth in access to radiotherapy services, driven by expanding hospital networks and increasing healthcare budgets. As healthcare systems become more centralized or privatized, increased investments in advanced radiotherapy equipment and software promote market growth and improve treatment accessibility.

Canada North America Radiotherapy Market Insight

The Canada radiotherapy market is expected to register the CAGR of 9.3% from 2025 to 2032, driven by expected to increasing healthcare expenditure for cancer treatment, growing government initiatives toward cancer treatment and rising patients’ awareness towards cancer treatment.

North America Radiotherapy Market Share

The North America radiotherapy market is primarily led by well-established companies, including:

• Siemens Healthcare GmbH (Germany)
• Hitachi, Ltd. (Japan)
• General Electric Company (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• Elekta (Sweden)
• ZEISS International (Germany)
• IBA Worldwide (Belgium)
• Canon Medical Systems Corporation (Japan)
• Accuray Incorporated (U.S.)
• Mevion Medical Systems (U.S.)
• Brainlab (Germany)
• BEBIG Medical (Germany)
• LinaTech, Inc. (China)
• United Imaging Healthcare Co., Ltd. (China)
• Eckert & Ziegler BEBIG (Germany)
• ViewRay Systems, Inc. (U.S.)
• Nordion (Canada) Inc. (Canada)
• P-Cure (Israel)

Latest Developments in North America Radiotherapy Market

• In May 2024, Siemens Healthineers and Varian unveiled new advancements in radiation oncology at ESTRO 2024, including HyperSight imaging, ARIA CORE oncology management, and more accessible MRI for radiotherapy
• In September 2024, Ballad Health has entered a 10-year, USD 260 million collaboration with Varian, a Siemens Healthineers company, to transform cancer care in the Appalachian Highlands. This partnership will bring advanced oncology technology, including linear accelerators and digital management solutions, to six cancer centers, enhancing treatment precision and accessibility for rural communitie
• In 2023, Hitachi expanded its Digital Systems & Services (DSS) segment through cloud, AI, and IoT solutions. This included further development of its Lumada platform and integration of North AmericaLogic, an IT service company
• In May 2025, GE HealthCare is significantly expanding its radiation oncology portfolio at ESTRO 2025 with new AI-enabled solutions, including the MR Contour DL for efficient organ segmentation. They are also enhancing their Intelligent Radiation Therapy (iRT) software to integrate MR and AI-driven workflows, aiming for more precise and timely cancer treatment
• In April 2024, GE HealthCare has finalized its acquisition of MIM Software, a North America provider of medical imaging analysis and AI solutions. This strategic move bolsters GE HealthCare's portfolio, particularly in radiation oncology, by integrating MIM Software's advanced tools for image analysis, workflow automation, and AI-powered segmentation and contouring into its precision care strategy

SKU-1826